Tools   Select Another Resource Report Type

https://www.lookaheadtrial.org

16-center, randomized clinical trial investigating the long-term health consequences of an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity in overweight volunteers with type 2 diabetes. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. Participants will be followed for a total of 11 to 13.5 years from randomization. The primary hypothesis is that the incidence rate of the first post-randomization occurrence of a composite outcome, which includes * cardiovascular death (including fatal myocardial infarction and stroke), * non-fatal myocardial infarction, * hospitalized angina, and * non-fatal stroke, over a planned follow-up period of up to 13.5 years will be reduced among participants assigned to the Lifestyle Intervention compared to those assigned to the control condition, Diabetes Support and Education. Look AHEAD will also test for reductions in the incidence of three secondary composite outcomes and examine the effect of the intervention on cardiovascular disease risk factors, diabetes control and complications, general health, and quality of life, and psychological outcomes. The cost and cost-effectiveness of the Lifestyle Intervention relative to Diabetes Support and Education will be assessed. The Look AHEAD intensive lifestyle intervention ended September, 2012. Participants continue to be followed to determine the long-term effects of the intervention on health outcomes.

Proper citation: Look AHEAD (RRID:SCR_001490) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/44

Randomized controlled clinical trial to understand how increasing hemodialysis to six times a week from the standard of three times a week may result in improved heart health. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialyis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale. In addition, main secondary outcomes have been designated for each of seven outcome domains: 1) cardiovascular structure and function (change in LV mass), 2) health-related quality of life/physical function (change in the PHC), 3) depression/burden of illness (change in Beck Depression Inventory), 4) nutrition (change in serum albumin), 5) cognitive function (change in the Trail Making Test B), 6) mineral metabolism (change in average predialysis serum phosphorus), and 7) clinical events (rate of non-access hospitalization or death). Hypertension and anemia are also main outcome domains, but without designation of single first priority outcomes.

Proper citation: Frequent Hemodialysis Network Daily Trial (RRID:SCR_001527) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/47

Study designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied. All patients were treated with combination therapy of pegylated interferon and ribavirin for 48 weeks, and were followed for an additional 48 week safter cessation of therapy. 400 patients, half African-American and half Caucasian American, from 8 clinical centers with the goals of establishing rates of response to optimal current therapy in the two ethnic groups, identify factors predictive of response, establish patterns of viral kinetics in response to antiviral therapy, and test hypotheses concerning viral and host factors determining response to therapy. Four ancillary studies designed to elucidate biological and virological basis for non-response are also included in Virahep-C. Additionally, the study has central facilitates for pathology, the virological testing laboratory and a serum/tissue repository.

Proper citation: Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (RRID:SCR_001553) Copy   

•   Source: SciCrunch Registry

https://www.clinicaltrials.gov/study/NCT00392678?term=SALSALATE&viewType=Table&rank=8

Nationwide, randomized, double blind, multi-center research study to determine whether the drug salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study is conducted in two stages. The primary objective of the first stage is to select a dose of salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic control. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk.

Proper citation: TINSAL-T2D (RRID:SCR_001546) Copy   

•   Source: SciCrunch Registry

https://www.clinicaltrials.gov/study/NCT00580749

Randomized multi-center clinical trial designed to test whether duodenojejunal (DJ) feeding is more effective than nasogastric (NG) feeding in providing enteral nutrition to patients with severe acute pancreatitis. SNAP will enroll participants with severe acute pancreatitis admitted to the intensive care unit at eight clinical centers. Upon enrollment, participants are assigned to NG or DJ feeding and managed for up to 28 days or until weaned on to solid food. Follow-up continues until participants are discharged from the hospital or for a maximum of 60 days. Outcomes relate to feeding tolerance and failure, nutritional status, risk for life-threatening pancreatic/systemic complications, and hospital mortality.

Proper citation: Study of Nutrition in Acute Pancreatitis (RRID:SCR_001544) Copy   

•   Source: SciCrunch Registry

http://archives.niddk.nih.gov/patient/crisp/rp-crisp.aspx

A five-year prospective cohort study following 240 patients who have autosomal-dominant polycystic kidney disease (PKD) to determine whether changes in anatomic characteristics of their kidneys as measured by magnetic resonance imaging will be useful in providing surrogate measures for disease progression. CRISP's overall goal is to develop methods that would facilitate shortening the observation period necessary to determine efficacy of treatment interventions in PKD patients. Specific goals of this study are to: * Quantify cyst growth and ascertain severity of renal parenchymal involvement by sequential measurement of total kidney volume and the ratio of intact parenchyma to renal parenchyma occupied by cysts over time * Establish useful clinical correlations of imaging data with other markers of disease progression * Identify and test other potential markers or indices of disease progression, for example, assessment of loss of heterozygosity of renal cells shed in the urine, or other markers, in cohorts of patients with PKD * Gain information about the cost-effectiveness, patient acceptability, and advantages and disadvantages of different imaging techniques used serially in patients with PKD. Some experience has been gained in establishing that repeat imaging of the same PKD patient, using these techniques, yields reproducible estimates of kidney size and the proportion of renal parenchyma occupied by cysts. MRI may also have the advantage of permitting simultaneous estimation of GFR. Ultrasound has the advantage of being more cost-effective and perhaps more acceptable to patients for repetitive studies, but the measurements may be less accurate and reproducible. Nonetheless, there is very limited experience in applying these techniques to follow progression of the renal disease. Development of improved, reproducible imaging methods that assess cyst growth and provide markers of disease progression could markedly improve the feasibility of clinical trials. Participating clinical centers are Emory University, the Mayo Clinic, University of Kansas, and the University of Alabama at Birmingham. The data coordinating and imaging analysis center is at Washington University. (PI has since moved to University of Pittsburgh) The study found that kidney enlargement resulting from the expansion of cysts is continuous, quantifiable, and associated with the decline of renal function. Cystic expansion occurs at a consistent rate per individual, although it is heterogeneous in the population, and that larger kidneys are associated with more rapid decrease in renal function. These anatomic characteristics of patient kidneys may provide useful surrogate measures for disease progression, and hence enhance the development of targeted therapies for autosomal dominant PKD. CRISP III is a five-year prospective cohort study to follow ~170 remaining autosomal dominant polycystic kidney disease (ADPKD) patients who were part of the original CRISP cohort study. CRISP III will verify and extend the preliminary observations of CRISP to determine the extent to which quantitative (kidney volume and blood flow, and hepatic and kidney cyst volume) or qualitative (cyst distribution and character) structural parameters predict renal insufficiency and develop and test new metrics to quantify and monitor disease progression. Urine metabolites and the genome will be correlated with the progression of disease to look for new, predictive disease biomarkers. This information from CRISP III will help determine if the kidney enlargement, blood flow, cyst distribution, or urine metabolites can function as an informative surrogate measure for disease progression.

Proper citation: Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (RRID:SCR_000690) Copy   

•   Source: SciCrunch Registry

http://anya.igsb.anl.gov/Geneways/GeneWays.html

System for automatically extracting, analzying, visualizing and integrating molecular pathway data from the research literature. System focuses on interactions between molecular substances and actions, providing a graphical consensus view on the collected information. GeneWays is designed as open platform, allowing researchers to query, review and critique integrated information.

Proper citation: GeneWays (RRID:SCR_000572) Copy   

•   Source: SciCrunch Registry

http://www.biooptions.com/

BIO - OPTIONS provides human tissues and biological materials to researchers and scientists for molecular and genomic research. These high quality, well characterized biological specimens are available for drug and biomarker discovery, validation of drug targets and development of diagnostic tests and devices. BIO - OPTIONS specializes in providing fresh tumor tissue, blood and other biological fluids delivered the same day or overnight for your studies. We collect specimens from virtually all disease states through our extensive network of physicians, hospitals, and clinical laboratories. All of our specimens are collected at facilities located in the United States in compliance with all applicable federal and state laws and regulations and ethical guidelines. Collection facilities are located on the East and West coasts and Midwest. The officers of BIO - OPTIONS consist of licensed physicians with extensive medical training and experience. This enables us to work directly with physicians and support staff to insure that collection protocols provide the high quality specimens needed for research without compromising patient care. Protocols are designed to work within the workflow of physician offices and hospital operating rooms so that specimens are timely processed and preserved and well characterized.

Proper citation: Bio-Options (RRID:SCR_004594) Copy   

•   Source: SciCrunch Registry

http://www.shca.org.cn/english/content/11540

The Institutional Tissue Bank (ITB) of Fudan University Shanghai Cancer Center was established in 2006 with the goal of serving as a central repository for human tissue samples for cancer research and possible personalized medicine for the institution. The Institutional Research Board oversees the fulfilling of informed consent of each patient whose samples are collected. The ITB''s collection procedures meet the global quality standards and provide high quality tissue samples. The quality control for morphology, RNA, DNA and protein has been set up to ensure the sample quality. Routine frozen section from tissue aliquot is made for every piece of sample to ensure the component of tumor tissue and the pathological feature is the same as the diagnosed tumor. Agilent 2100 Bioanalyzer was used to provide RNA and DNA quality parameters. The Tissue Bank occupies 500 m2, with sufficient space for sample preparation and storage, data registration, data tracking/access, related equipments and monitor system. Variant samples including blood, tumor tissue, and body fluids are collected and serve as alternative permanent patient tissue records. Annotation of collected samples is captured through linking the medical record and pathological report system to tissue bank software. Frequent tumor types such as lung cancer, breast cancer, gastric cancer, urological tumors, gynecological tumors and esophageal cancers, head & neck cancers, as well as infrequent cancer types such as malignant soft tissue sarcomas, pancreatic cancer, gall bladder cancer, and other rare cancers are all collected and stored. Tumor tissues are stored with matched normal tissues. Serum and plasma are isolated from coagulation plus and coagulation minus blood samples. White blood cells are stored as well. Tissues are stored both in RNALater at -20 degrees C and -80 degrees C after snap frozen. Samples have been increased from 4,000 in 2008 to 10,783 in 2009. To the end of September 2010, over 30,000 samples has been processed and stored in our tissue bank. As planned, 50,000 samples will be stored dynamically. Over 50 funded projects have used the samples from our tissue bank. Productive papers have been published in the past years by using the samples. More and more projects will be approved to get research resources from tissue bank in the future. The tissue bank of FUSCC has been designated as the key subject and successful model by Shanghai municipal government.

Proper citation: Cancer Center Tissue Bank - Fudan University (RRID:SCR_004596) Copy   

•   Source: SciCrunch Registry

http://www.beadonor.org

Founded in 1986, Washington Regional Transplant Community (WRTC) is federally designated as the organ procurement organization (OPO) for Washington, DC, Northern Virginia and suburban Maryland since 1988. This non-profit organization provides full-service organ, tissue and eye recovery. WRTC responds to potential donors at more than 44 area healthcare institutions and serves approximately 5.13 million Washington-area residents. It coordinates with all five area transplant centers and the United Network for Organ Sharing (UNOS). WRTC provides support to more than 4,000 donor family members and acts as the community and professional education resource for organ and tissue donation in the Washington, DC, region.

Proper citation: Washington Regional Transplant Community - WRTC (RRID:SCR_004628) Copy   

•   Source: SciCrunch Registry

http://www.fccc.edu/prevention/studies/biosample/about.html

Fox Chase has developed a facility dedicated to the collection and distribution of human subject biosamples and supporting personal and family cancer history data. In response to announcement (CA-00-025; P30 CA06927S2), the Fox Chase Cancer Center''s Biosample Repository (BR) and Tumor Bank Facility (TBF) is making blood specimens (i.e., whole blood, plasma, platelet-rich plasma, platelet homogenates, red blood cells, leukocytes, lymphoblastoid cell lines, and DNA isolated from leukocytes) and tumor tissues (i.e., multi-tissue microarrays and tumor DNAs) collected by our facilities available for research. Request for blood and tissue will be reviewed by a panel of scientists and ranked. Priority will be given to those investigators with current NIGH/NCI funding, but will be made available as recommended by the internal and external advisory committees. * Blood Inventory: Plasma, Serum, Whole Blood, Lymphocytes, DNA * Tissue Inventory: Tumor and Normal Adjacent Tissue, Fresh-Frozen, Formalin-Fixed Paraffin-Embedded Tissue, OCT Embedded Tissue, Ethanol-fixed Tissue

Proper citation: Fox Chase Biosample Repository Core Facility (RRID:SCR_004746) Copy   

•   Source: SciCrunch Registry

http://www.brainbankforautism.org.uk/

Encourages and facilitates brain tissue donation for use in the best scientific studies to better understand the biological basis of autism down to the cellular and molecular levels and through that understanding bring about the development of effective interventions for those affected by autism spectrum disorders. To ensure the best co-ordinated use of brain tissue, the UK Brain Bank for Autism works in collaboration with the Autism Tissue Program in the US and shares the same Tissue Advisory board. The Brain Bank for Autism & Related Developmental Research was established in 2009. It is an initiative to develop a similar program in the UK to the Autism Tissue Program, which has been developed in the US since 1998. Our Brain Bank is the first extension outside the US of the Autism Tissue Program and is integrated with it. The Brain Bank is based at Oxford University, where it forms part of the Thomas Willis Oxford Brain Collection. It operates in accordance with all UK legal and ethical requirements. The donation of post-mortem brain tissue for this research program is of fundamental importance to our understanding of the causes of autism and to help us develop more effective diagnostic measures and interventions. A separate brain bank for autism is necessary because we need to understand how, in autism, the brain develops over time and how the brain functions as a whole. However, our Brain Bank will promote close cooperation across all relevant brain banks in order to take the research forward. Our research focuses on: * people within the autism spectrum or their family members * people not affected by autism but who are affected by epilepsy * individuals without autism or epilepsy.

Proper citation: Brain Bank for Autism (RRID:SCR_004664) Copy   

•   Source: SciCrunch Registry

http://www.thellf.org

The Living Legacy Foundation is the non-profit organ and tissue donation program serving the state of Maryland, with the exception of three counties (Charles, Montgomery, and Prince Georges). We facilitate the life-saving process of organ and tissue donation, celebrate the generous gifts of organ and tissue donors, support our donor families and educate others about the importance of registering as a donor. Our organization was incorporated in 1990, consolidating the former Maryland Organ Procurement Center and the Maryland Tissue Bank. The U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services accredits us as an organ procurement organization, and the State of Maryland licenses us as a Tissue Bank. Our tissue bank is accredited by the American Association of Tissue Banks. We are governed by a 25 member Board of Directors, which includes general public members, transplant recipient representatives and donor family members. Our Board also includes transplant physicians, surgeons and administrators from the two Baltimore organ transplant centers (the University of Maryland Medical Center and The Johns Hopkins Hospital).

Proper citation: Living Legacy Foundation of Maryland (RRID:SCR_004665) Copy   

•   Source: SciCrunch Registry

http://cancer.case.edu/sharedresources/tissue/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. The Case Comprehensive Cancer Center''s Biorepository and Tissue Processing Core Facility (BTPC) serves two primary functions: 1. To build an inventory of remnant human tissues, blood and other body fluids (collectively termed biospecimens) targeted towards cancer and other medical research, for later assignment to investigators; and 2. To provide long term, controlled storage of biospecimens for specific researchers. These samples are for research purposes only and may not be used for clinical diagnosis or implantation into humans. Clinical information relating to the samples and donors are collected and maintained in a secure database. Samples and data are de-identified or de-linked before release to the researcher unless he/she has specific IRB approval to gain access to this information. Remnant biospecimens are prospectively collected from surgical procedures, autopsies and clinical laboratories for the BTPC by the Human Tissue Procurement Facility (HTPF), which operates under UH-IRB Protocol 01-02-45. Blood and bone marrow specimens are collected for the BTPC by the Hematopoietic Stem Cell Core Facility (HSCC), which operates under UH-IRB Protocol 09-90-195. The Division of Surgical Pathology at University Hospitals Case Medical Center (UHCMC) has clinical archives of paraffin blocks that can be made available through the BTPC for retrospective research studies under the approval of the Vice Chair for Clinical Affairs at UHCMC. Surgical Pathologists associated with the BTPC are responsible for determining which blocks can be made available and how much material can be removed from the blocks. Types of Tissue Available * Malignant, benign, diseased, normal and normal human tissues * Normal adjacent tissues available paired with tumor specimens in many cases * Tissues are collected from over 50 anatomic sites * Frozen specimens, OCT-embedded and paraffin-embedded tissues * Large array of paraffin-embedded specimens from clinical archives of paraffin blocks and QC research blocks maintained by the HTPF * Peripheral blood and bone marrow samples from initial visits and follow-up procedures are processed to obtain serum and cell fractions for storage * No samples are collected from individuals with known infectious illnesses * Fetal biospecimens are not collected due to state and local statutes

Proper citation: Case Comprehensive Cancer Center Biorepository and Tissue Processing Core Facility (RRID:SCR_004382) Copy   

•   Source: SciCrunch Registry

http://www.uclaaidsinstitute.org/researchareas/clinical_malignancy.php

THIS RESOURCE IS NO LONGER IN SERVICE, documented on February 27, 2012. The National Cancer Institute established centers in the United States and its territories for the collection and distribution of tissues, blood and secretions from patients with clinically-characterized AIDS related malignancies in 1994. The AIDS Malignancy Bank makes these tissues available to qualified investigators in the United States for research on AIDS malignancies. It is hoped that by providing access to these high-quality specimens, research in AIDS-related malignancies will be encouraged and expanded. The AMB contains formalin-fixed paraffin-embedded tissues, fresh-frozen tissues, malignant-cell suspensions, fine-needle aspirates, and cell lines from AIDS-related malignancies. The bank also contains serum, plasma, urine, bone marrow, cervical secretions, anal swabs, saliva semen and multi-site autopsy tissues from patients with AIDS-related malignancies who have participated in clinical trials. The bank has an associated database that contains prognostic, staging, outcome and treatment data on patients from whom tissues were obtained. Researchers pay for preparation and shipping of specimens.

Proper citation: AIDS Malignancy Bank (RRID:SCR_004417) Copy   

•   Source: SciCrunch Registry

http://www.procure.ca/en/biobank/

PROCURE proposes to enable the collection and storage of standardized high volumes of prostatic tissues, blood, urine, clinical information and socio-demographic data from men undergoing prostate cancer screening and surgery across the province of Quebec and facilitate access to these resources. PROCURE will make the Biobank materials and information available to the global scientific community to facilitate the implementation of studies at an accelerated pace. Informed consent, upholding full confidentiality, will be sought from the thousands of men already undergoing prostate biopsies and radical prostatectomies in Quebec each year. Quebec is an ideal location to conduct this initiative with its diverse ethnic groups and low migration. The low migration will allow for repeated follow-up with individuals. This large collection of biospecimen and information will be used for biochemical and genetic analysis with great statistical power and will facilitate learning about the manifestation and progression of prostate cancer over time. Additional benefits include the acceleration of clinical trials, better prevention, earlier detection and diagnosis, the development of personalized medicine, more efficacious treatment, and follow-up care. The Biobank is a collaborative organization with long term partnerships established between PROCURE, the four Qu��������bec universities (McGill University, Universit�������� de Sherbrooke, Universit�������� Laval, Universit�������� de Montr��������al), with the Fonds de recherche en sant�������� du Qu��������bec and other key groups to be confirmed over time.

Proper citation: PROCURE Quebec Prostate Cancer Biobank (RRID:SCR_004411) Copy   

•   Source: SciCrunch Registry

http://www.genelogic.com/services/biorepository-biobanking

THIS RESOURCE IS NO LONGER IN SERVICE, documented on February 08, 2013. A biorepository containing thousands of biosamples from international pharmas, biotechs, hospitals, medical centers, private physicians and universities. As a part of our custodial activities, we have on-site power generators, extra supplies of liquid nitrogen and regular inspections. Sample tracking is handled by our LIMS system, which is connected to our laboratory service work, ensuring integrity of sample tracking and sample identification. Our biorepository group also handles sample collection kits, constructing kits with relevant tubes, accession sheets and barcode labels. The group also tracks expiration of tubes. Having a biorepository is also major advantage for serving the needs of clinical trials. It decreases costs, as there is lesser need for shipping samples. It mitigates the risk associated with sample transfer and handling. It simplifies trial management, fewer partners to manage. It simplifies chain of custody, sample transfer occurs under a single LIMS at a single site with teams that work together each day. It simplifies processing any sample repeats, no tracking, cost or risks associated with inter-company transfers. We can also supply sample collection kits complete with accession sheets and matched barcode labels.

Proper citation: Gene Logic Biorepository and Biobanking (RRID:SCR_004654) Copy   

•   Source: SciCrunch Registry

http://www.barthsyndrome.org/english/View.asp?x=1513

The Barth Syndrome Registry and Repository (BRR) at the University of Florida and Children''s Hospital Boston was created to provide additional information about this rare disorder. By collecting information directly from families and abstracting medical information from patient records, we hope to build a large anonymized database that is useful for answering scientific research questions and that is a source of medical information. Additionally, we are collecting blood samples for DNA isolation and storage and for the development of special cell lines. These tools will allow researchers to better understand the cellular and genetic nature of this disease and how these abnormalities may impact the clinical variability of Barth syndrome patients. Currently available data from the Barth Syndrome Registry and Repository includes self-reported data. This includes basic demographics, age at diagnosis of Barth Syndrome, reason for diagnosis, family history; symptoms, presence or absence of a history of cardiomyopathy, history regarding hospitalizations, cardiac transplant or listing for transplant, presence or absence of a history of neutropenia; history of infections, medical therapy and basic developmental history. We are in the process of abstracting medical data to build a more complete medical database and may be able to provide additional data with a specific request. Currently the DNA bank has data from 65 patients, genomic DNA from 50 patients, lymphoblast lines from 41 patients, fibroblast lines from 3 patients, and myocardium/autopsy from 3 patients. However, this is increasing as new patients enroll in the Registry. Please contact us with questions and specific requests about data or specimens.

Proper citation: Barth Syndrome Biorepository (RRID:SCR_004775) Copy   

•   Source: SciCrunch Registry

http://www.ntnu.edu/lbk/biobank

The Regional Biobank of Central Norway, henceforth called the Biobank, is a research facility which contains a collection of human biological material such as blood, tissue and urine samples, and a database which stores relevant information about the samples and the patients from whom the samples originate, as well as information obtained from analysis of the material. The material is collected as part of medical examinations, diagnosis or treatment. The Biobank is foreseen to give an increased knowledge about causes for diseases and their mechanisms, and thereby contributing to improve prophylactic health work, diagnostics and treatment. The Biobank is owned and operated by official authorities on a no commercial profit basis. The Biobank was established in collaboration between the Central Norwegian Regional Health Authority (data management and administration) and the Faculty of Medicine at the Norwegian University of Science and Technology (economics and personnel). The Biobank is approved by The Data Inspectorate of Norway, and by the Regional Committee for Medical Research Ethics, and all information in the Biobank is handled according to the guidelines of the Data Inspectorate.

Proper citation: Regional Biobank of Central Norway (RRID:SCR_004534) Copy   

•   Source: SciCrunch Registry

http://www.clinicbiobanc.org/en_index.html

A biobank of repositories which works to obtain, store, manage and distribute large collections of human biological samples of phenotypes and diseases of marked interest for researchers. The biobank sample collection is made up of three extensive repositories. The Neurological Tissue Biobank is a nervous tissue repository (brain and spinal cord) created from donations from cadavers with or without neurological conditions. It helps facilitate research in neurological illnesses. The Tumour Biobank and Anatomical Pathologies Collections is a repository of tumorous tissue and samples from cancer patients. The Blood and Fluid Biobank is a repository which contains samples of metabolic, inflammatory bowel, hepatic, digestive and maternal and foetal diseases, among others. It houses a large range of samples of scientific interest, primarily DNA, serum and plasma.

Proper citation: Biobank of Hospital Clinic - IDIBAPS (RRID:SCR_004530) Copy   

•   Source: SciCrunch Registry